Abstract:Despite decades of efforts, non-small-cell lung cancer (NSCLC) remains the leading cause of cancer mortality globally primarily due to the challenge in early detection of the cancer. Being an important player in cancer development, the dysregulated miRNAs have been shown promising values as non-invasive diagnostic and prognostic biomarkers for NSCLC. The aim of our study is to access the efficacy and reliability of a potential circulating miRNA panel in early diagnosis of NSCLC. We first selected eight candidate miRNAs, miR-146b, miR-205, miR-29c, miR-31, miR-30b, miR-337, miR-411, and miR-708, which have been shown frequently aberrant in primary NSCLC patients based on our previous studies and other reports. The serum level of each of these miRNAs was evaluated by quantitative real-time PCR (qRT-PCR) in training and testing sets. We found that 5 out of 8 miRNAs (miR-146b, miR-205, miR-29c, miR-30b, and miR-337) were significantly up- regulated in NSCLCs patients compared to healthy or cancer-free controls in both training and testing sets. Based on the logistic regression model, a 4-miRNAs set (miR-146b, miR- 205, miR-29c and miR-30b) was picked out of the 5 miRNAs owing to its excellent diagnostic power for NSCLC patients in the training set (AUC=0.99, accuracy=95.00%), the testing set (AUC=0.93, accuracy=89.69%), and the training-testing combined set (AUC=0.96, accuracy=92.00%). When pathological subtypes of NSCLC are compared, this 4-miRNA panel carried a relatively higher prediction power and higher sensitivity for adenocarcinoma (AC) (AUC=0.98, sensitivity=99.10%) than for squamous cell carcinoma (SCC) (AUC=0.93, sensitivity=90.32%). Additionally, this panel demonstrated a comparable diagnostic capacity for stage I (AUC=0.96) and stage II-III (AUC=0.95) of NSCLC, suggesting its role in reflecting the tumor load. Importantly, the high levels of miR-146b and miR-29c in serum were significantly associated with poor 5-year overall survival (OS) (both p=0.04). Further survival analysis showed that high level of miR-146b in serum is specifically correlated with poor survival rate in SCC patients (p=0.0035) but not in AC patients (p=0.83), consistent with our previous finding that the high tissue expression of miR-146b in lung cancer specimen is indicative of a poor prognosis for SCC patients. Altogether, our study demonstrated that the 4-miRNA panel is a novel, sensitive and non-invasive serum marker for the early diagnosis of NSCLC.

Next-Generation Sequencing of Micrornas for Breast Cancer Detection

Analysis of Serum Genome-Wide Micrornas for Breast Cancer Detection.

Circulating Micrornas As Specific Biomarkers for Breast Cancer Detection

Identification of Microrna Biomarkers in the Blood of Breast Cancer Patients Based on Microrna Profiling.

A circulating miRNA signature as a diagnostic biomarker for non-invasive early detection of breast cancer

Identification of a six‐miRNA panel in serum benefiting pancreatic cancer diagnosis

Serum Microrna Profiling and Breast Cancer Risk: the Use of Mir-484/191 As Endogenous Controls

Serum Microrna-155 As A Potential Biomarker To Track Disease In Breast Cancer

Identification and Validation of Circulating MicroRNA Signatures for Breast Cancer Early Detection Based on Large Scale Tissue-Derived Data.

Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases

Identification of Serum Mir-1915-3p and Mir-455-3p As Biomarkers for Breast Cancer.

Identification of Serum Mirnas by Nano-Quantum Dots Microarray As Diagnostic Biomarkers for Early Detection of Non-Small Cell Lung Cancer

Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping

Serum Microrna Signature Is Capable Of Early Diagnosis For Non-Small Cell Lung Cancer

Expression Profile Of Circulating Micrornas As A Promising Fingerprint For Cervical Cancer Diagnosis And Monitoringy

Identification and characterization of novel serum microRNA candidates from deep sequencing in cervical cancer patients

Identification of Ten Serum Micrornas from a Genome‐wide Serum Microrna Expression Profile As Novel Noninvasive Biomarkers for Nonsmall Cell Lung Cancer Diagnosis

Abstract 1477: Circulating miR-125a-3p and miR-451a may be liquid biopsy biomarkers for the diagnosis of breast cancer

Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer.

Expression Profile of Micrornas in Serum: A Fingerprint for Esophageal Squamous Cell Carcinoma

Identification of Serum miR-501-3p and miR-338-3p as Novel Diagnostic Biomarkers for Breast Cancer and Their Target Genes Associated with Immune Infiltration